UBS

UBS just initiated coverage on nine biotech stocks, four of which its analysts have given ‘Buy’ ratings – and two of those, the analysts believe, could soar by more than 50%. For these four biotech stocks that investors should buy, according to UBS, as well as the five biotech stocks that the firm initiated coverage on at a ‘Neutral’ rating,…